Gonadotroph pituitary neuroendocrine tumour (non-functioning adenoma): lines of therapy

Cancer page →

2 standard-of-care settings across 2 lines and 1 biomarker subgroup. Rows come from the cancer page's standard of care; the grid places each on its line and subgroup.

Line	All comers
Second line	1
Other settings	1

Second line

Subgroup	Setting	Approach	Products and trials	Guideline	Evidence
All comers	Visual compromise, growth or recurrence	Transsphenoidal surgery; radiotherapy or radiosurgery for residual or recurrent tumour; temozolomide for aggressive tumours.	Stereotactic radiosurgery (Gamma Knife, CyberKnife, linac SRS)TemozolomidePituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma		89

Other settings

Subgroup	Setting	Approach	Products and trials	Guideline	Evidence
All comers	Incidental, away from the chiasm	Observation with MRI and visual fields.	Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma		-

Lines and subgroups are parsed from the setting text of each standard-of-care row and can misclassify an unusual phrasing; the row’s own setting is always shown. Guideline chips reflect the NCCN category and ESMO-MCBS grade recorded on the cancer page, checked on its stated date. Not medical advice.